No­var­tis nabs FDA ap­proval for hyped Eylea ri­val

As Re­gen­eron’s Eylea stares down po­ten­tial slow-death-by-gener­ics, No­var­tis has nabbed a wide­ly ex­pect­ed FDA ap­proval for its own wet mac­u­lar de­gen­er­a­tion in­jec­tion, Beovu (brolu­cizum­ab).

No­var­tis has been eye­ing Re­gen­eron patent ex­pi­ra­tion with the leer­ing in­ten­si­ty of a prowl­ing tiger. Be­fore be­com­ing CEO in 2017, Vas Narasimhan iden­ti­fied brolu­cizum­ab as one of four big late-stage drugs to watch, and in 2018 he named it one of the “core 5” in his list of 25 block­busters.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN